EN

Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination ...

HALAMKA, Magdalena, Jakub CVEK, Jiří KUBEŠ, Eva ZÁVADOVÁ, Pavel KOMÍNEK, Jaroslav HORÁČEK, Ladislav DUŠEK a David FELTL. Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer. Oral oncology, 2011, roč. 47, č. 8, s. 763-767. ISSN 1368-8375. doi:10.1016/j.oraloncology.2011.05.009.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer
Autoři HALAMKA, Magdalena (203 Česká republika), Jakub CVEK (203 Česká republika), Jiří KUBEŠ (203 Česká republika), Eva ZÁVADOVÁ (203 Česká republika), Pavel KOMÍNEK (203 Česká republika), Jaroslav HORÁČEK (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí) a David FELTL (203 Česká republika, garant).
Vydání Oral oncology, 2011, 1368-8375.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 3.2 Clinical medicine
Stát vydavatele Nizozemsko
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 2.857
Kód RIV RIV/00216224:14110/11:00053158
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.oraloncology.2011.05.009
UT WoS 000293002800017
Klíčová slova anglicky Head and neck cancer; Celecoxib; Radiotherapy; VEGF; COX-2 expression
Příznaky Mezinárodní význam
Změnil Změnil: Mgr. Michal Petr, učo 65024. Změněno: 12. 4. 2012 07:29.
Anotace
Celebrex and radiotherapy in advanced head and neck cancer. This phase I dose-escalation study seeks to determine the phase II recommended dose of cyclooxygenase type 2 (COX-2) inhibitor in patients with locally advanced squamous cell head and neck (H&N) cancer, treated with accelerated radiotherapy. Anti-vasculogenic effect of this treatment on serum vascular endothelial growth factor (VEGF) is examined. Patients were irradiated with curative intent (72 Gy in 6 weeks). Celecoxib was administered throughout the radiotherapy course. Serum VEGF level were tested during radiotherapy and in follow-up. Tumor specimens were stained to quantify the COX-2 expression. Thirty-two patients completed the treatment. The dose of celecoxib was escalated (200, 400 and 800 mg bid, then de-escalated to 600 mg bid). The acute toxicity related to the treatment in the first and second cohort did not reach grade III; in the third cohort three patients had grade III radiation toxicity and one had celecoxib-related toxicity. In the last fourth cohort the toxicity was acceptable. Significant VEGF level drop (p = 0.011) was found between radiation day 1 and post-treatment visit. Significant decrease (p = 0.022) of the VEGF level was shown in patients with high COX-2 expression in the tumor. Phase II recommended dose of celecoxib combined with accelerated radiotherapy in advanced H&N cancer was 600 mg bid. A significant decrease of the post-treatment serum VEGF level compared to the initial level was noticed only in patients with high COX-2 expression in tumors.
VytisknoutZobrazeno: 19. 4. 2019 14:46

Další aplikace